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Background: Epithelial-mesenchymal transition (EMT) is defined as switching of polarized epithelial cells to a
migratory fibroblastoid phenotype. EMT is known to be involved in the progression and metastasis of various
cancers. The aim was to evaluate that whether EMT-related proteins' alterations are associated with
clinicopathological features and prognosis in lung adenocarcinoma.
Methods: The expression of EMT-related proteins including cytokeratin, E-cadherin, TTF-1, β-catenin, vimentin, Snail,
Twist, CD44 was evaluated by immunohistochemistry using a tissue array method in the lung adenocarcinoma
tissues of 95 patients. In addition, clinicopathological characteristics and survival were compared with the
expression of EMT-related proteins.
Results: Loss of epithelial proteins and/or acquisition of the expression of mesenchymal proteins were observed in
lung adenocarcinoma. These proteins’ alteration was associated with poor cell differentiation and poor patients’
outcome, respectively. Subjects were divided into two groups according to the number of EMT-related proteins’
alteration. A higher number of EMT-related proteins’ alteration was found to be significantly associated with
unfavorable outcome. Multivariate analysis showed that a higher number of EMT-related proteins’ alteration was
independently associated with poor prognosis.
Conclusions: The number of EMT-related proteins’ alteration is a significant prognostic marker to predict overall
survival in patients with lung adenocarcinoma. The information generated will be valuable for the prognosis of
patients with lung adenocarcinoma.
Virtual slides: The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
1007838329872974
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Non-small cell lung cancer is the leading cause of cancer
death worldwide. Among non–small cell lung cancer
variants, adenocarcinoma is the most common histo-
logical subtype. Surgical resection is the treatment of
choice for early-stage adenocarcinoma. However, tumor
recurrence and metastasis are the most common events
encountered after resection that lead to mortality [1,2].
Chemotherapy and radiotherapy are common treatment* Correspondence: fqmeng2004@126.com
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reproduction in any medium, provided the ormodalities applied to patients with recurrent adenocar-
cinoma [3], but the combination modality did not
significantly improve patients’ survival. Since tumor me-
tastasis is the main obstacle for long-term survival after
surgical resection, identification of molecular markers
related to metastasis may better predict the prognosis in
patients with lung adenocarcinoma.
Epithelial-mesenchymal transition (EMT) consists of a
rapid and often reversible change of cell phenotype.
During EMT, cells lose or redistribute epithelial proteins
and acquire mesenchymal proteins. As a result, cells loss
epithelial polarity and acquire a spindle-shaped, highly
motile fibroblastoid phenotype. This transition involves. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ment membrane [4-7] and a developmental program of
tumor cells [8,9]. The phenomenon of EMT is proved
during various of numerous cancers, e.g. pancreatic cancer,
gastric, and colorectal carcinomas [10-13]. It is an important
event in the progression, invasion and metastasis of carcin-
omas which have a particularly dismal prognosis [5,7,14].
In this study, using a tissue array method, we investigated
the expression of known EMT-related proteins including
cytokeratin, E-cadherin, TTF-1, β-catenin, vimentin, Snail,
Twist, CD44 in lung adenocarcinoma patients’ samples.
The aim was to evaluate changes in EMT-related protein
and to investigate their association with clinicopathological
parameters and prognosis in lung adenocarcinoma.
Materials and methods
Patients’ samples
From January 2007 to December 2009, 95 patients
undergoing surgical resection for lung adenocarcinoma
at Nanjing Drum Tower Hospital were enrolled in this
study. Clinicopathological parameters such as age,
gender, cell differentiation and pathological stage were
evaluated by reviewing pathological records. The mean
patient age was 58 years. Samples were obtained from 56
(58.8%) male and 39 (41.2%) female patients, and there
were 51 (53.7%, I-II stage) cases of early-stage adenocar-
cinoma and 44 (46.3%, III-IV stage) cases of advanced-
stage adenocarcinoma. Thirty-three patients (34.7%)
were poorly differentiated adenocarcinoma and sixty-two
(65.3%) were well and moderately differentiated adenocar-
cinoma. Outcomes were determined from the date of
surgery until death or June 2012. The study was approved
by the Medical Ethics Committee of the Affiliated Drum
Tower Hospital of Nanjing University Medical School.
Tissue microarray construction
The tissue microarray was created from tissue blocks that
had been stored at approximately 24°C. Hematoxylin and
eosin-stained sections were reviewed to select representa-
tive areas of tumor, and then to acquire cores for the
microarray. The tissue microarray block was constructed
with a precision instrument (Beecher Instruments, Sun
Prairie, WI). Core tissue biopsies (1 mm in diameter) were
taken from individual donor blocks and arranged in a new
recipient beeswax block (tissue array block). Sections
(2 μm) were consecutively cut and placed on positively
charged slides for use in immunohistochemical staining.
Immunohistochemical staining, scoring
Immunohistochemistry for cytokeratin, E-cadherin, TTF-1,
β-catenin, vimentin, Snail, Twist, CD44 were performed
(Table 1). Slides were placed in a 60°C oven for 30 minutes,
deparaffinized, and rehydrated through xylenes and
graded ethanol solutions to water. Antigen retrieval wasperformed by a steamer method in which the specimens
were placed in a 0.01 mol/L EDTA solution (pH = 8) for
30 minutes at 94°C using a steamer. Primary antibodies
were applied overnight at 4°C, followed by incubation at
room temperature with horseradish peroxidase (HRP)
conjugated anti-mouse secondary antibody for cases of
each primary antibody. Appropriate positive and negative
controls were used for the immunohistochemical analysis.
After staining, if any case on one slide represented a miss-
ing core missing, displacement, or undetectable cancer
cells or mucosal glands, the corresponding paraffin-
embedded tissue block was recut and restained. Evaluation
of the cell staining reaction was performed in accordance
with the following immunoreactive score (IRS) proposed
by Remmele and Stegner with slight modification as fol-
lows: IRS = SI (staining intensity) × PP (percentage of
positive cells). SI was determined as 0, negative; 1, weak;
2, moderate; and 3, strong. PP was defined as 0, negative;
1, 1-10% positive cells; 2, 11-50% positive cells; 3, 51-80%
positive cells; 4, >80% positive cells. IRS value ≥ 4 was con-
sidered as a positive staining result [15].
Statistical analysis
Comparison of the variables was performed using Student’s
t test, Fisher’s exact test or Pearson’s χ2 test, depending on
the nature of the data. Correlation analysis was performed
using Spearman’s correlation analysis. Survival curves were
estimated using the Kaplan–Meier product-limit method,
and the significance of differences between survival curves
was determined using the log rank test. Multivariate ana-
lysis was performed by Cox proportional hazards regres-
sion modeling. All statistical tests were two-sided, and
statistical significance was accepted at the p < 0.05 level. All
analyses were performed using SPSS version 11.0.
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The alteration of EMT-related proteins and their
correlation with clinicopathological factors in lung
adenocarcinoma
Losing frequencies of Epithelial proteins were 25.3% for




Figure 1 Immunohistochemistry findings showing epithelial protein l
adenocarcinoma. A Cytoplasmic cytokeratin loss. B Membranous E-cadhe
expression. E Cytoplasmic vimentin expression. F Nuclear Snail expression.Aberrant expression frequencies of mesenchymal proteins
were 47.4% for β-catenin, 40.0% for vimentin, 60.0%for
Snail, 68.4% for Twist, 41.1% for CD44 (Figure 1).
The alteration of TTF-1, vimentin, Snail and CD44
were found to be significantly associated with poorly cell
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p-valuePoorly Well and moderately I-II III-IV
(%) (%) (%) (%)
Loss of epithelial protein expression
Cytokeratin 8(24.2) 16(25.8) 0.867 11(21.6) 13(29.5) 0.372
E-cadherin 19(57.6) 35(56.5) 0.916 29(56.9) 25(56.8) 0.997
TTF-1 20(60.6) 17(27.4) 0.002 16(31.4) 21(47.4) 0.103
Acquisition of mesenchymal protein expression
β-catenin 19(57.6) 26(41.9) 0.146 23(45.1) 22(50.0) 0.633
Vimentin 18(54.5) 20(32.3) 0.035 14(27.5) 24(54.5) 0.007
Snail 26(78.7) 31(50.0) 0.006 29(56.9) 28(63.6) 0.502
Twist 25(75.8) 40(64.5) 0.262 35(68.6) 30(68.2) 0.963
CD44 20(60.6) 19(30.6) 0.005 22(43.1) 17(38.6) 0.657
Table 3 Univariate analysis for overall survivals of 95
patients with lung adenocarcinoma
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differentiation existed in tumor EMT-related proteins
expression among groups of age, gender. The association
of EMT-related proteins' staining and the clinicopatho-
logical characteristics are summarized in Table 2.
The association between epithelial protein and mesen-
chymal protein expression was demonstrated by the
Pearson χ2 test. Losing of cytokeratin and E-cadherin
were significantly associated with β-catenin (p = 0.029,
p < 0.001) and Twist (p = 0.006, p = 0.028) expression. Los-
ing of TTF-1 was found to be significantly associated with
β-catenin (p = 0.006) and vimentin (p = 0.026) expression.
The alteration of EMT-related proteins as prognostic
factors in patients with lung adenocarcinoma
To investigate the prognostic impact of EMT-related
proteins' alterations in lung adenocarcinoma, Kaplan-
Meier survival analyses were carried out. In terms of the
epithelial proteins, the loss of cytokeratin (p = 0.0224),
E-cadherin (p = 0.0132) and TTF-1 (p = 0.0208) were
found to be significantly associated with a poor outcome.
For mesenchymal proteins, the expression of vimentin
(p = 0.0022), Snail (p = 0.0454), CD44 (p = 0.0167) were
found to be significantly associated with a poor outcome
(Table 3).
To investigate the accumulative effects of EMT-related
proteins’ alteration on the prognosis of lung adenocar-
cinoma, the patients were divided into two groups
according to the number of EMT-related proteins’ alter-
ation: EMT-N1 (one to four protein changes occurred in
62 cases), EMT-N2 (more than four protein changes
occurred in 33 cases). Patients with EMT-N2 showed a
more unfavorable prognosis than those with EMT-N1
(p < 0.0001, Figure 2A). TNM stage and EMT-N were
entered into multivariate analyses. To control for potential
confounders, age, gender, and cell differentiation were also
entered into multivariate analyses. Multivariate analysesshowed that TNM stage (p < 0.001), cell differentiation
(p = 0.030) and EMT-N (p = 0.002) were independent
prognostic markers for overall survival (Table 4).
Patients with EMT-N2 showed a more unfavorable
prognosis than those with EMT-N1, and this was true
for early-stage lung adenocarcinoma (stage I and II, n =
51). For early-stage lung adenocarcinoma in the study,
patients with EMT-N2 had significantly worse overall
survival than those with EMT-N1 (p = 0.0001, Figure 2B).
Multivariate analysis identified EMT-N was also an inde-
pendent prognostic marker for overall survival in early-
stage lung adenocarcinoma (HR = 0.405, 95% CI = 0.180
to 0.908, p = 0.028).
AB
Figure 2 Survival curves using the Kaplan–Meier method by log rank test. A EMT-N in all cases. B EMT-N in TNMI-II cases.
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Non-small cell lung cancer (NSCLC) is the most pre-
dominant type of lung cancer and the leading cause of
cancer death worldwide [16]. Deletions or insertions in
exon 19 and point mutations in exons 18 and 21 in the
epidermal growth factor receptor are special diagnostic
value in advanced-stage non-small cell lung cancerpatients [17,18]. Expression of oncofetal protein IMP3
correlates with distant metastases regardless of histo-
logical subtype of lung adenocarcinoma [19]. Promoter
methylation was associated with clinicopathologic char-
acteristics and may be served as a potentially increased
risk factor for pleural indentation of NSCLC [20]. These
groups have used different sets of markers to predict the
Table 4 Multivariate analyses for overall survivals of 95
patients with lung adenocarcinoma
Variables HR(95% CI) p-value
TNM stage
I-II
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Shi et al. Diagnostic Pathology 2013, 8:89 Page 6 of 8
http://www.diagnosticpathology.org/content/8/1/89prognosis and survival of patients with NSCLC with some
success. However, there is little by using a combination of
metastasis-related markers. Epithelial-mesenchymal tran-
sition (EMT) is considered to be one of the major molecu-
lar mechanisms inducing tumour invasion and metastasis.
Some study showed that centrally located tumour cells
stained positively for epithelial markers, but it was absent
at the invasive front of the tumour in lung cancer [21-23].
So the expression of EMT-related proteins which related
to metastasis may better reflect and predict the prognosis
and survival in patients with NSCLC. In our study the aim
was to evaluate changes in EMT-related proteins and to
investigate their association with prognosis in lung
adenocarcinoma.
As the epithelial markers, E-cadherin and cytokeratin
expression is strongly related to positive serosal involve-
ment, infiltrating type, poorly differentiated histology
[13,24]. Thyroid transcription factor-1 (TTF-1) is a tran-
scription factor that is expressed in approximately 75%
of lung adenocarcinoma. Several studies demonstrated
an independent lower risk of death for lung adenocar-
cinoma patients whose tumor expresses positive TTF1
staining [25]. Recently one paper suggested that TTF-1
is an important EMT-related marker. It inhibits EMT
and restores epithelial phenotype in lung adenocarcin-
oma cells [26]. As a result, a novel aspect of TTF-1 is
that losing expression of TTF-1 made tumor cells gener-
ating EMT and then resulting in the worse prognosis of
patients. The above reports and our findings indicate
that loss of E-cadherin, cytokeratin and TTF1 expression
is an important indicator of EMT. The regulators involv-
ing mesenchumal differentiation such as β-catenin, Snail,
Twist are considered to regulate EMT by strong repres-
sion of E-cadherin expression [11,27,28]. Our study
showed that the acquisition of mesenchymal protein ex-
pression tended to correlate with loss of epithelial pro-
tein expression. CD44 has been identified as a specific
marker of cancer stem cells. In addition, CD44 plays an
important role in tumor cells undergoing an EMT-like
process and associated with cancer progression [29,30]. Inthe present study we have demonstrated that the expres-
sion of various EMT-related proteins is associated with a
poor prognosis in lung adenocarcinoma. Our results sup-
port previous reports where the expression of various
EMT-related molecule were associated with neoplastic
progression and poor survival in some malignancies.
Characteristics of EMT include complete loss of epi-
thelial polarity, loss of epithelial markers and acquisition
of mesenchymal markers. In addition to processes in-
volving complete EMT, many processes occurring during
development and in adult organisms involve only a tran-
sient loss of epithelial polarity without full acquisition of
mesenchymal characteristics. We have defined as partial
EMT [31,32]. Partial EMT has been suggested to occur
in some metastatic cancers and the number of EMT-
related proteins’ alteration may reflect the degree of
EMT in a way [33]. So in our study, we divided the pa-
tients into two groups according to the number of EMT-
related proteins’ alteration. The results showed that the
patients with higher number of EMT-related proteins’
alteration had a significantly shorter overall survival. In
multivariate analyses the number of EMT-related pro-
teins’ alteration was significant independent prognostic
indicators for overall survivals. This finding suggests
that higher number of EMT-related proteins’ alteration
may be significantly related to tumor progression and
metastasis.
There is increasing evidence to support the role of
postoperative adjuvant chemotherapy in locally advanced-
stage lung cancer. However, the effect of adjuvant chemo-
therapy in early-stage adenocarcinoma remains to be
determined [34]. In the study we analyzed the predictive
ability of the number of EMT-related proteins’ alteration
in patients with early-stage lung adenocarcinoma. For
early-stage lung adenocarcinoma (stage I and II) there is a
trend toward worse overall survival in patients with a
higher number of EMT-related proteins’ alteration. The
number of EMT-related proteins’ alteration was significant
independent prognostic indicators for overall survivals for
early-stage adenocarcinoma in multivariate analyses. The
results suggest that the number of EMT-related proteins’
alteration may be able to identify the poor prognostic
cases in early-stage lung adenocarcinoma. Adjuvant ther-
apy may be considered in patients with early-stage lung
adenocarcinoma when patients have a higher number of
EMT-related proteins’ alteration.
Conclusions
The present study showed mainly two results. One was
that the number of EMT-related proteins’ alteration is a
independent prognostic marker to predict overall sur-
vival in patients with lung adenocarcinoma. The infor-
mation generated will be valuable for the prognosis of
patients with lung adenocarcinoma. The other was that
Shi et al. Diagnostic Pathology 2013, 8:89 Page 7 of 8
http://www.diagnosticpathology.org/content/8/1/89the number of EMT-related proteins’ alteration is also a
independent prognostic marker to predict overall in pa-
tients with early-stage (stage I and II) lung adenocarcin-
oma. The information generated will be valuable for
determining the adjuvant chemotherapy for patients
with early-stage lung adenocarcinoma.
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